Fubotv earnings beat by $0.10, revenue topped estimates
Thomas J. Schuetz, the Chief Executive Officer of Compass Therapeutics, Inc. (NASDAQ:CMPX), recently purchased 10,000 shares of the company’s common stock. The shares were acquired on May 27, 2025, at a weighted average price of $2.11 per share, totaling approximately $21,100. The purchase comes as the stock has gained nearly 34% over the past six months, with analyst price targets ranging from $6 to $32. According to InvestingPro analysis, the stock is currently trading near its Fair Value. Following this transaction, Schuetz holds 6,480,825 shares directly.
This acquisition includes shares purchased in two separate transactions, with prices ranging from $2.105 to $2.115 per share. Schuetz’s holdings also encompass a significant number of unvested restricted stock units (RSUs) subject to service-based vesting conditions.
In other recent news, Compass Therapeutics has made significant strides in its clinical programs, particularly with its drug candidate tovecimig. The company has initiated a new clinical trial for biliary tract cancer (BTC) at The University of Texas MD Anderson Cancer Center, with the first patient already dosed. This trial aims to evaluate tovecimig in combination with a standard treatment regimen for BTC, focusing on progression-free survival and safety. Additionally, Compass Therapeutics announced positive results from its COMPANION-002 Phase 2/3 trial, where tovecimig combined with paclitaxel showed a statistically significant improvement in overall response rate compared to paclitaxel alone.
H.C. Wainwright has maintained its Buy rating and $24 price target for Compass Therapeutics, reflecting confidence in the potential of tovecimig. The firm highlighted the recent advancements in Compass’s clinical trials as a significant factor in its endorsement. Similarly, Leerink Partners upgraded Compass Therapeutics’ stock rating from Market Perform to Outperform, raising the price target to $6.00. This upgrade was influenced by the company’s ongoing clinical programs and future milestones, such as the anticipated Phase 2 study for CTX-471 in mid-2025.
Compass Therapeutics’ research efforts also include CTX-471, which targets CD137 in solid tumors and has shown potential in preclinical studies. The company is actively developing its pipeline, with future trials planned for other candidates like CTX-8371 and CTX-10726. These developments underscore Compass Therapeutics’ commitment to advancing oncology treatments and reflect positively on its growth prospects, as highlighted by analyst firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.